Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Diffuse Parenchymal Lung Disease
When do you consider systemic therapy for patients with progressive fibrosing mediastinitis?
Related Questions
What is your approach to managing ILD associated with inflammatory bowel disease?
Do you utilize cytokine panels to guide treatment of patients with EGPA?
How do you approach pre-operative risk assessment and optimization in a patient with interstitial lung disease?
Would you consider using steroids in patients with respiratory failure caused by aspiration pneumonitis?
What strategies are effective for managing cough in patients receiving inhaled treprostinil?
What is the role of inebilizumab in the maintenance treatment of IgG4-related disease?
What are your thoughts on using abatacept for RA-associated ILD in a patient undergoing treatment for CLL with zanubrutinib, and how would you assess the potential increased risk of infection in this context?
Do you seek pathologic confirmation before proceeding with empiric immunosuppressive therapy in symptomatic patients with radiographic NSIP?
How long after initiating mycophenolate do you wait before tapering prednisone off in patients with myositis-associated ILD?
Are there certain clinical features that help you choose between benralizumab and mepolizumab for EGPA in clinical practice?
